Filing Details

Accession Number:
0000899243-21-022069
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-06-04 17:00:53
Reporting Period:
2021-06-02
Accepted Time:
2021-06-04 17:00:53
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1847903 Centessa Pharmaceuticals Plc CNTA Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1863418 L Tia Bush C/O Centessa Pharmaceuticals Plc
3Rd Fl., 1 Ashley Rd, Altrincham
Cheshire X0 WA14 2DT
Chief Quality Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Ordinary Shares Acquisiton 2021-06-02 3,000 $20.00 3,000 No 4 P Indirect By spouse
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect By spouse
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Ordinary Shares Share Option (right to buy) Acquisiton 2021-05-07 500,338 $0.00 500,338 $9.42
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
500,338 2031-05-07 No 4 A Direct
Footnotes
  1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
  2. On May 20, 2021, the Issuer effected a share capital reorganization, which had the effect of a one for two reverse share split of the Issuer's share capital ("Share Split"). This amount has been adjusted to give effect to the Share Split.
  3. This transaction occurred prior to the effectiveness of the Issuer's registration under Section 12 of the Securities Exchange Act of 1934 and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3
  4. 25% of the shares subject to such option shall vest and become exercisable on May 20, 2022 and the remaining 75% of the shares subject to such option shall vest and become exercisable in 36 monthly installments on the first day of each month thereafter..
  5. Represented A Ordinary Shares that were redesignated as Ordinary Shares immediately prior to the closing of the initial public offering.